21 June 2011 in Analytical Letters
A new specific monoclonal antibody against the organophosphorous pesticide fenthion was produced based on our previous study. A sensitive and specific Enzyme-Linked Immunosorbent Assay (ELISA) for fenthion based on the new immunizing/coating hapten combination was developed. In this study, the H1 which attempts to expose the aromatic ring group was conjugated with bovine serum albumin (BSA) for the immunogen. All of the haptens that have been synthesized were conjugated with ovalbumin (OVA) for the coating antigen. The efficient antibody/coating conjugated combinations were selected, and the optimized ELISA was developed. In the optimized system, the IC50 value was 5.8 ng · mL−1 with the detection limit (IC20) of 0.028 ng · mL−1. The cross reactivity with all of the tested pesticides was lower than the 0.5%. Also, the system can detect the fenthion addition to the real samples such as soil, water, rice, and Chinese cabbages.
26 February 2021 in Medicine
Background: Varicose veins of the lower extremities are common chronic venous diseases in the clinic. Although Western medicine has various surgical methods to treat varicose veins in the lower extremities, there are still a variety of complications. Some studies have shown that Buyang Huanwu decoction treatment of varicose veins of the lower extremities has a certain effect, and can reduce the occurrence of postoperative complications, but there is no evidence of evidence-based medicine. The research carried out in this scheme is to systematically evaluate the efficacy and safety of Buyang Huanwu decoction in the treatment of varicose veins in the lower extremities, and to provide reliable evidence for guiding clinical practice. Methods: This is a randomized, double-blind, placebo-controlled, parallel-group clinical trial, which studies the effectiveness and safety of Buyang Huanwu decoction in the treatment of varicose veins of the lower extremities. The patients are randomly and evenly divided into treatment group and control group, the former one is given Buyang Huanwu decoction and the latter one is given placebo. The study will last 49 days, including a 7-day washout period, 14-day intervention and 28-day follow-up, focusing on its efficacy and safety indicators. Observation indicators include: TCM syndrome score, Venous Clinical Severity Score (VCSS), Venous Disability Scote (VDS), Aberdeen Varicose Vein Questionnaire (AVVQ), Hemorheology Indicators, Adverse Reactions, etc. Data analysis is performed using SPSS 25.0 software. Discussion: This study will evaluate the effectiveness and safety of Buyang Huanwu decoction and provide clinical evidence for the treatment of varicose veins of the lower extremities. Trial registration: OSF Registration number: DOI 10.17605/OSF.IO/WGJXT.